Cerenkov luminescence (CL) imaging is a new molecular imaging modality that utilizes the photons emitted during radioactive decay when charged particles travel faster than the phase velocity of light in a dielectric medium. Here we present a novel agent to convert and increase CL emission at longer wavelengths using multimodal protein microspheres (MSs). The 64 Cu-labeled protein microspheres contain quantum dots (QDs) encapsulated within a high-refractive-index-oil core. Dark box imaging of the MSs was conducted to demonstrate the improvement in CL emission at longer wavelengths. To illustrate the versatile design of these MSs and the potential of CL in disease diagnosis, these MSs were utilized for in vitro cell targeting and ex vivo CL-excited QD fluorescence (CL-FL) imaging of atherosclerotic plaques in rats. It was shown that by utilizing both QDs and MSs with a high-refractive-index-oil core, the CL emission increases by four-fold at longer wavelengths. Furthermore, we demonstrate that these MSs generate both an in vivo and ex vivo contrast signal. The design 
Introduction
Molecular imaging has become an indispensable tool in biomedical research by providing spatially-resolved molecular information for drug development and diagnosis of various diseases (Weissleder and Pittet 2008, Xu et al 2011) . Nuclear imaging techniques, such as PET and SPECT, have been shown to provide valuable information in both the research and the clinical settings (Dobrucki and Sinusas 2010, Thorek et al 2012) . A recent development has been the ability to optically visualize radioactive decay signals from medical isotopes, known as Cerenkov luminescence (CL) imaging (Robertson et al 2009 , Ruggiero et al 2010 . Cerenkov luminescence imaging may offer relatively lower cost molecular imaging capabilities for screening applications, compared to PET and SPECT, and has the potential for bridging the information acquired from nuclear and optical imaging.
Cerenkov luminescence imaging utilizes the principle of Cerenkov radiation generation (Mitchell et al 2011) , which is analogous to the sonic boom phenomenon. During Cerenkov radiation, the electron distribution in the medium is disrupted as the charged particle travels through the medium and loses kinetic energy by polarizing surrounding electrons (Ruggiero et al 2010) . These polarized molecules re-equilibrate through emission of ultra violet (UV) and visible light when the speed of the charged particle exceeds the phase velocity of light, giving the observed CL (Robertson et al 2009 , Ruggiero et al 2010 , Mitchell et al 2011 . Unlike fluorescence emission, CL emission is directional, with a continuous and broad spectrum that extends from the UV to the near-infrared (NIR) (Ruggiero et al 2010 , Mitchell et al 2011 . The production of CL can be described by the Frank-Tamm formula (Mitchell et 
where dN/dx is the number of photons generated per distance, α is the dimensionless finestructure constant (1/137), n is the refractive index of the medium, and β is the ratio of particle velocity to the speed of light (v/c) (Mitchell et al 2011) . Equation (1) shows that CL emission is inversely proportional to the square of the wavelength (λ), indicating CL emission is greater at shorter wavelengths (Jelley 1955 , Robertson et al 2009 , Ruggiero et al 2010 , Mitchell et al 2011 . In addition, the intensity of CL generated in materials increases with higher refractive index (Robertson et al 2009 , Mitchell et al 2011 . This can be explained by considering the relationship between refractive index and the minimum threshold energy at which CL light may be emitted. Since the phase velocity of light decreases with increasing refractive index, the minimum threshold kinetic energy for the particles therefore decreases, and results in higher production of CL light (Jelley 1955) . The concept of CL imaging was demonstrated in the pre-clinical setting using a sensitive charged-couple device (CCD) camera to detect CL generated from β-emitting (both electrons and positrons) isotopes (Robertson et al 2009) . Furthermore, several research groups independently showed the feasibility of utilizing CL imaging for disease targeting and drug tracking in small animals (Mitchell et al 2011 , Xu et al 2012 . However, one primary limitation of using CL in biomedical imaging is its short-wavelength emission, which is strongly absorbed by biological chromophores such as hemoglobin and melanin (Boschi and Spinelli 2012) , making CL imaging of deeper tissues challenging. To overcome this limitation, it has been proposed that quantum dots (QDs) could serve as a suitable CL conversion agent due to their broad continuous UV-blue absorption spectrum which overlaps with the emission spectrum of CL, their high quantum efficiency, and large Stokes shift (Wu et al 2003 , Smith et al 2008 , Dothager et al 2010 , Liu et al 2010 , Boschi and Spinelli 2012 . This spectral shift phenomenon was previously characterized as Cerenkov radiation energy transfer (CRET) (Dothager et al 2010) . To use CL to excite a fluorescent agent and generate an emission in the longer-wavelength region, the absorption and emission spectra of the fluorescent agent need to be well separated. Since QDs have a large Stokes shift, they can be readily excited by CL, and the resulting optical emission can be shifted to longer wavelengths which are more suitable for deep-tissue imaging (Dothager et al 2010 , Liu et al 2010 .
Since the output of CL increases with higher refractive index (Mitchell et al 2011) , CL emission can potentially be further increased by utilizing protein-shell microspheres (MSs) that contain a high-refractive-index core. These MSs consist of a vegetable oil core and a hydrophilic shell made of cross-linked bovine serum albumin (BSA) subunits (Toublan et al 2006) . In this study, we encapsulated QDs in MSs that have a high-refractive-index-oil core to increase CL, and rely on the QDs to wavelength-shift the emission into the NIR. Furthermore, we utilized these MSs for targeting atherosclerotic lesions as a proof-of-concept study to demonstrate the versatile design of these MSs as a targeted contrast agent with the potential for biomedical imaging.
Materials and methods

Quantum dot microsphere preparation
The QD stock solution with an 800 nm emission peak (Qdot 800 ITK organic quantum dots, 1 μM in decane, 4 mL solution, Invitrogen) received from the manufacturer was mixed with four times the volume of isopropanol/methanol mixture (75/25 volume ratio) in a sealed test tube. The mixture was then centrifuged at 3000 rpm for 5 min to separate the QDs and the solvent. The supernatant fluid (decane and isopropanol/methanol solvent) was removed, and the QDs were re-suspended in 1 mL of vegetable oil. Each batch of MSs was composed of 4 mL of 5% BSA solution and 1 mL of the QD-oil suspension. The process of encapsulating the QD-oil suspension within the BSA shell was mediated through sonication, utilizing high-frequency ultrasound (20 kHz) delivered by a 1 cm diameter acoustic horn at an acoustic power of 35 W cm −2 for 3 min (John et al 2012) . During the process, the BSA protein subunits cross-linked through sonochemical formation of disulfide bonds via inter protein cysteine oxidation (Toublan et al 2006 , John et al 2012 . Following sonication, the MS emulsion was repeatedly washed with cold 5% BSA solution and centrifuged at 5000 rpm for 3 min to remove excess reagents.
Targeted microsphere surface modification
Before use, MSs were first centrifuged and washed with 1 × PBS at pH 8 to remove excess BSA. To ensure longer circulation time, MSs were PEGylated. The PEG reagent, (N-hydroxysuccinimide)-(polyethylene glycol) 5k -maleimide (NHS-PEG 5k -MAL, JenKem, U.S.A.), was prepared by dissolving the compound in anhydrous dimethylformamide (DMF, Sigma-Aldrich). The concentration of MSs was first determined using the Lowry assay (Peterson 1977) , and the PEG reagent was then mixed at a 5:1 (PEG/BSA) ratio with the MSs suspended in PBS. The mixture was rotated for one hour to allow the PEG agent to covalently bind to the amine on the BSA shell of the MSs. Afterward, MSs were centrifuged at 5000 rpm for 3 min to remove the unlabeled reagent. The PEGylated MSs were subsequently re-suspended in 1 × PBS solution at pH 7.4.
To target the α v β 3 integrin overexpressed on atherosclerotic lesions (Hoshiga et al 1995 , Winter et al 2003 , Burtea et al 2008 , the PEGylated MSs were functionalized with the cyclic RGD peptide (cRGD). The cyclo (Arg-Gly-Asp-D-Phe-Cys) (cRGDfc, Peptide International) compound was first activated using a tris (2-carboxyethyl) phosphine reducing agent (TCEP, Sigma-Aldrich) in 1 × PBS solution at pH 7.4. After activation, the cRGD solution was combined with the PEGylated MS suspension. The mixture was subsequently rotated for 30 min at room temperature to allow binding between the thiol groups on the cRGD and the maleimide groups on the PEG. Cyclic RGD-functionalized PEGylated MSs were then centrifuged and washed to remove excess reagents and re-suspended in 1 × PBS solution at pH 7.4.
Non-targeted microsphere surface modification
The non-targeted MSs were PEGylated using the NHS-PEG 5k -CH 3 (JenKem, U.S.A.) compound, which is PEG with methyl groups at the terminal end instead of maleimide groups. The PEGylation procedure was identical to that described previously for the targeted MSs. Cyclic RGD functionalization was not performed after the PEGylation step.
Copper-64 isotope labeling
A solution of 64 CuCl 2 in ammonium acetate (Washington University, St. Louis, MO) containing the Copper-64 ( 64 Cu, t 1/2 = 12.7 h) radioactive isotope was incubated with the surface-modified MSs for one hour at 28 °C. After the incubation, the MS suspension was washed with PBS and centrifuged in centrifuge tube filters to remove unlabeled isotope. The labeled MSs were re-suspended in 1 × PBS solution at pH 7.4. The stability of 64 Cu labeling was evaluated using thin-layer chromatography (TLC), and more than 95% of the MSs remained labeled after 24 h.
In vitro cell targeting
Human breast cancer cell lines, MDA-MB-231 and MCF-7, were acquired from ATCC (Manassas, VA), and the human umbilical vein endothelial cell line (HUVEC) was purchased from Lonza (Lonza Group, Ltd, Switzerland). Cells were seeded and prepared 24 hrs prior the experiment. Before introducing the MSs, the cell media in each culture dish was aspirated and fresh media was added to the culture dish. The cells were then incubated with 100 μL of 2 mM manganese solution in PBS for 10 min to activate the α v β 3 integrins (Jackson et al 1997) . After activation, MSs were added to the cells (10 4 MSs/cell dish) and allowed to incubate for one hour. Prior to fluorescence microscopy, all cell samples were washed using 1 × PBS to remove any dead cells and excess MSs.
Animals
Animals were cared for in accordance with a protocol approved by the University of Illinois at Urbana-Champaign Institutional Animal Care and Use Committee (IACUC). To compare the difference in optical intensity between CL and CL-FL in tissue, equal doses and volumes of 64 Cu isotope and 64 Cu-labeled QD-MSs were subcutaneously injected at different skin locations in a previously sacrificed C57/BL6 mouse. The mouse was then imaged using the luminescence dark box system (Stanford Photonics, Palo Alto, CA).
For in vivo atherosclerotic lesion targeting, Wistar-Furth rats were fed either regular rat chow (control animals) or a high-lipid rat chow with a high dose of vitamin D2 to induce atherosclerotic plaques. One milliliter of a cRGD-functionalized MS suspension (10 9 MSs mL −1 ) labeled with approximately 500 μCi of 64 Cu isotope was injected into each animal (n = 3) through the jugular vein and allowed to circulate for one hour. The injection was followed by in vivo PET-CT scanning, then ex vivo dark box imaging and gamma well counting of tissue specimens. Another group of animals (n = 2) was injected with non-targeted MSs to evaluate the non-specific binding.
Statistical analysis
For both the in vitro cell targeting study and the in vivo atherosclerotic plaque study, optical signals were measured across six different locations on the samples, and the average and standard deviation of the signal intensities were calculated. In addition, Student's t-tests were performed on all experimental data to determine the statistical significance, and to evaluate the difference in targeting efficiency between the targeted and the non-targeted MSs.
Results
Fabrication and characterization of 64 Cu-labeled QD-MSs
For the CL and CL-FL imaging in this study, QDs with an 800 nm emission peak were encapsulated in the vegetable oil core of the MSs. The BSA shell was labeled with 64 Cu isotope, a positron-emitting PET isotope that generates positrons with sufficient energy to produce CL (Dothager et al 2010 , Ruggiero et al 2010 . To demonstrate QD-MSs as a targeting agent, the BSA surface of MSs was modified through PEGylation to extend in vivo circulation time (Veronese and Pasut 2005, Madani et al 2007) (supplementary figure 1 stacks.iop.org/ PMB/60/020727/mmedia), and cyclic RGD peptide was attached to target the α v β 3 integrin overexpressed in atherosclerotic lesions (Hoshiga et al 1995 , Winter et al 2003 , Burtea et al 2008 . The microstructure of these MSs is shown in the schematic ( figure 1(a) ), as well as in the scanning electron microscope (SEM, figure 1(b) ) and transmission electron microscope (TEM, figure 1(c) ) images. The average size of the MSs measured using a Coulter counter (Beckman Coulter, Inc.) was 1.52 ± 1.07 μm.
Dependence of CL intensity on refractive index
To illustrate the relationship between CL intensity and refractive index, and to verify that MSs do not alter the basic properties of CL published previously (Mitchell et al 2011) , we prepared MSs composed of different types of hydrophobic liquid cores (without QDs): fluorocarbon (electronic fluid fluorinert FC-43, 3 M), vegetable oil (Crisco, J.M. Smucker Co.), and wintergreen oil (methyl salicylate, Sigma-Aldrich) with refractive indices of 1.25, 1.46, and 1.54, respectively (Lide 2005) . The three types of MSs were prepared at equal concentration, labeled with equal doses of 64 Cu (100 μCi), and imaged for one minute using a commercial dark box (Stanford Photonics, Inc.) to measure CL luminescence intensity. The system utilized a cooled (−21 °C) intensified CCD (iCCD) (XR Mega 10) with a selectable emission filter wheel. Figure 2 (a) illustrates CL images of different MSs using a short pass (<500 nm) emission filter. Results show that at the same level of radioactivity, CL intensity from MSs with a vegetable oil core was approximately four-fold higher than from MSs with a fluorocarbon core, and the CL intensity from MSs with a wintergreen oil core was approximately three-fold higher than from MSs with a vegetable oil core ( figure 2(b) ). Our experimental results can also be validated using equation (1), which clearly shows that a higher refractive index will increase the number of CL photons generated per distance dN/dx. This outcome is expected since dN/dx is directly proportional to 1 − 1/(β 2 n 2 ).
Wavelength-shifting of CL to NIR
With vegetable oil MSs, we further showed that the integration of NIR QDs increased the emission intensity at longer wavelengths. An optical emission intensity comparison study was performed between 64 Cu-labeled vegetable oil MSs with and without QDs. Samples were imaged using the luminescence dark box under both short pass (<500 nm) and long pass (>600 nm) emission filters for 1 min each. Optical signals detected under the short pass filter would predominantly be CL, since QDs have a narrow emission peak and would not be detected (Wu et al 2003 , Smith et al 2008 . Optical signals acquired under the long pass filter would include CL-excited QD fluorescence (CL-FL) and a small portion of CL due to its relatively weaker emission at longer wavelengths (Ruggiero et al 2010 , Mitchell et al 2011 . Dark box imaging confirmed that while MSs without QDs emitted a stronger signal intensity at shorter wavelengths, MSs with QDs emitted a much stronger intensity at longer wavelengths ( figure 2(c) ). We further investigated the difference in optical emission through tissue between 64 Cu-labeled QD MSs and 64 Cu in PBS at longer wavelengths, which served as a direct comparison between CL-FL from MSs and the commonly used pure CL from radioactive isotopes. The mouse for this experiment was injected subcutaneously with 200 μL (20 μCi) of each sample at different skin locations (figure 2(d)), and then imaged using the luminescence dark box. We observed an approximately four-fold higher optical emission from the MSs. 
In vitro cell targeting
64 Cu-labeled QD-MSs were tested for in vitro targeting of α v β 3 integrin to demonstrate the capability of these MSs as a targeting agent. We chose this specific integrin receptor based on previous successful targeting results using the same MSs (Toublan et al 2006) . Quantum dot-MSs were functionalized with cRGD peptide, and human umbilical vein endothelial cells (HUVEC) were used, since this cell line is known to express α v β 3 integrin (Sriramarao et al 1993) . Three experimental groups were tested: a control group with PBS solution, a targeted group with cRGD-functionalized MSs, and a non-targeted group with non-functionalized MSs to evaluate for any nonspecific binding. The three groups of cells were subsequently imaged using a fluorescence microscope (Axiovert 200, Zeiss), and targeting efficiency was determined based on average fluorescence intensity (figures 3(a)-(c) ).
The cell study revealed an approximately three-fold higher binding of cRGD-functionalized MSs than the non-specific binding by the non-functionalized MSs (p < 0.001, figure 3(d) ). In addition, we observed clusters of MSs adhering to the HUVEC cells in the targeted group ( figure 3(a) ). These clusters contributed to the saturating fluorescence signals seen in the corresponding fluorescence image. A more diffuse fluorescence, most likely from endocytosed or degraded MSs, was also observed in the cytoplasm of these cells, which was not attributed to autofluorescence, given the absence of autofluorescence in the control sample ( figure 3(c) ). Additional cell studies were also conducted using human breast cancer cell lines to further determine the targeting specificity of the functionalized MSs (supplementary figure 2 stacks. iop.org/PMB/60/020727/mmedia).
In vivo targeting and ex vivo CL-FL imaging of atherosclerotic plaques
To examine the targeting efficiency of 64 Cu-labeled cRGD-functionalized PEGylated QD-MSs as a potential in vivo targeting agent and the potential use of CL imaging for disease detection, we performed a proof-of-concept study of in vivo targeting of atherosclerotic plaques in a hyperlipidemic rodent model. Atherosclerosis was selected as a disease model since we had previously demonstrated ex vivo targeting of atherosclerotic plaques using MSs (Kim et al 2014) . The spatial distribution of MSs and the CL-FL was assessed in vivo using a microPET-CT scanner (Inveon, Siemens Healthcare) and ex vivo in the excised rat aortas using the luminescence dark box. Biodistribution of MSs was also examined with post-mortem gamma well counting.
In vivo PET-CT showed scattered PET signals around the aortic arch after one hour of MS circulation ( figure 4(a) ; red arrows). The animals were then euthanized, and their aortas were excised for CL-FL imaging. Excised tissue was imaged for five minutes under the long pass emission filter, and CL-FL signal was observed primarily from the aortic arch and thoracic aorta ( figure 4(b) ). To verify the CL-FL signal, the same segment of aorta was also imaged using a fluorescence dark box (Maestro, CRi, Inc.) equipped with a 445-490 nm excitation filter and an 800 nm long-pass emission filter. The locations of signal were relatively consistent with the results from CL-FL imaging (figure 4(c)), with slight differences due to re-positioning of the aortas and different sensitivity levels between the two systems. In addition to optical imaging, the same aorta segments, along with blood and skin samples, were analyzed with a gamma well counter (Wizard2, Perkin Elmer) to directly measure the radioactivity in the tissue specimens. Data confirmed that the aorta had higher radioactivity levels than blood and skin, and the aortic arch showed higher activity levels than the thoracic aorta segment (figure 4(d) stacks.iop.org/PMB/60/020727/mmedia). These findings were consistent with the optical imaging results.
The in vivo study was also repeated using non-functionalized MSs to evaluate in vivo targeting efficiency. CL-FL imaging of excised aorta showed low optical signal intensity (supplementary figure 3(a) stacks.iop.org/PMB/60/020727/mmedia). Furthermore, the same aorta revealed weak QD fluorescence during subsequent fluorescence imaging (supplementary figure 3(b) stacks.iop.org/PMB/60/020727/mmedia). Average CL-FL intensity emitted from the aortas with targeted and non-targeted MSs was measured. Signal intensity from the targeted MSs was approximately three-fold higher than that from the non-targeted MSs (p < 0.05, figure 4(e) ).
Histology validation
To validate the imaging results and the presence of disease, histology was performed at different locations on the aorta, including the arch, where optical signals were obtained ( figure 4(b) , white line), and at a location on the thoracic aorta where no optical signal was detected (figure 4(b), green line). The hematoxylin and eosin (H & E)-stained histology sections were examined by a board-certified pathologist 'blinded' to the imaging results. Analysis confirmed that the histology sections from the aortic arch showed signs of early-stage fibrous plaques ( Figure  4 (f)) which contain collagen fibers (Bloom and Fawcett 1975, Wheater et al 1991) . Thickening of the tunica intima with accumulation of foam cells was also observed in this region, which is typical for atherosclerosis (Wheater et al 1991) . In contrast, these physiological characteristics were not observed in histology sections from regions of the thoracic aorta where no optical signals were evident ( figure 4(g) ). The tissue from this region appeared normal without thickening of the vessel wall. The histology sections of the aorta from the non-targeted study were also examined, and optical signals were not detected at histological sites where plaques were observed (supplementary figure 3(c) stacks.iop.org/PMB/60/020727/mmedia).
Discussion
The development of CL imaging has rapidly progressed since its first application in biomedical imaging, and quantitative characterization and disease screening using this technology, including clinical studies, have been demonstrated by various research groups (Spinelli et al 2013 , Thorek et al 2014 . However, practical challenges for CL imaging still exist. Due to the short-wavelength emission of CL, current applications are mainly limited to tumors or thyroid diseases that are located closer to the skin surface (Ruggiero et al 2010 , Spinelli et al 2013 , Thorek et al 2014 . While the combination of QDs with CL-emitting radioisotopes have been shown to shift CL emission toward longer-wavelengths, the amount of improvement in tissue penetration depth and signal intensity can be limited by the weak intensity of CL, which is attributed to the inefficient conversion process of β-particle energy to Cerenkov light (Mitchell et al 2011) . In our study, we have attempted to address this challenge by intensifying the CL used for QD excitation by altering the refractive index of the local medium where the CL is generated, named inside the core of the MSs.
Previous studies have shown that protein-shell oil-core MSs can be fabricated and modified for use in a variety of imaging modalities, including ultrasound imaging, magnetic resonance imaging (MRI), fluorescence imaging, and magnetomotive optical coherence tomography (MM-OCT) (John et al 2012 , Kim et al 2014 . In this study, we further modified the MSs to serve as an agent that is capable of enhancing and converting CL emission toward the NIR. We demonstrated that our MSs successfully enhanced the CL emission from 64 Cu isotopes by four-fold, indicating that CL emission can be intensified by increasing the refractive index of the MS core. Our results in mouse skin suggest that utilizing both a high-index oil core (n = 1.46), which is greater than the average refractive index of tissue (n = 1.38) (Tearney et al 1995) , and the QDs increases optical emission intensity through the skin at longer wavelengths, and can potentially improve CL imaging of deeper tissue.
In addition, our in vitro and in vivo findings demonstrated that 64 Cu-labeled QD MSs can be utilized as a multimodal imaging contrast agent for disease targeting, such as targeting of atherosclerotic plaques. Ex vivo CL-FL imaging of the excised aortas showed that the targeted QD-MSs have a significantly higher level of binding compared to the non-targeted MSs, which was validated by in vivo PET-CT scanning, ex vivo fluorescence imaging, and histology. The correlation among all imaging results suggests that CL imaging can be a reliable screening tool.
Conclusion
In conclusion, we have successfully fabricated radiolabeled protein-shell oil-core MSs that encapsulate QDs for CL-FL imaging. The unique and versatile design of these MSs can be readily modified for enhancing contrast signals in different imaging modalities, and the relatively large volume of the MS core offers the potential for use as a drug delivery capsule. In addition to the application employed in our study, these MSs together with CL imaging could be used as diagnostic tools for a variety of diseases, including cancer. This engineered and fabricated design that combines the advantages of a high-refractive-index core medium and the wavelength-shifting CL-FL technique has potential for in vivo CL imaging.
Further development of this imaging technology is needed to demonstrate clinical potential, such as the construction and use of an intravascular or intra-luminal catheter for CL imaging. Moreover, additional in vivo experiments are needed to evaluate and optimize the performance of the current MS contrast agent design to achieve better signal generation and contrast. Our study contributes to a growing number of investigations that continue to demonstrate the potential of CL imaging for biomedical applications.
